Adapalene Over the Counter: What FDA Label Data Shows
Adapalene belongs to the retinoid class of compounds — synthetic derivatives related to vitamin A that have long been used in prescription dermatology. What changed in recent years is that a 0.1% concentration of adapalene became available without a prescription in the United States, and official OTC drug label filings reflect this shift. The data retrieved from the openFDA label API offers a clear picture of exactly what these products are labeled to do, who should exercise caution, and what the regulated warnings cover.
What the Labeled Purpose Is
Across all eight OTC product records identified in the openFDA data, the labeled purpose is consistent: acne treatment. The labeled use, equally uniform across every filing reviewed, states the product is intended “for the treatment of acne.” There are no additional indications listed in the OTC label data — no anti-aging claims, no labeling for blackhead prevention as a separate indication, and no broader skin-condition uses. The regulatory scope, as reflected in these filings, is squarely and solely acne.
Strength and Active Ingredient: What Products on the Market Contain
Every product record in the openFDA dataset lists the active ingredient at the same concentration: Adapalene 0.1%. Several filings include the notation “(retinoid)” alongside the concentration, and multiple labels direct consumers to “read consumer information leaflet,” suggesting supplementary documentation accompanies the product. No products at higher concentrations — such as the 0.3% strength available by prescription — appear in this OTC dataset. The 0.1% figure is the consistent, uniform strength reflected across all manufacturer filings reviewed here.
Products Listed in the openFDA Data
| Brand Name | Active Ingredient / Strength | Labeled Purpose |
|---|---|---|
| Differin | Adapalene 0.1% (retinoid) | Acne treatment |
| Neutrogena Adapalene 0.1% Acne Treatment | Adapalene, USP 0.1% (retinoid) | Acne treatment |
| Proactiv MD Adapalene Acne Treatment | Adapalene 0.1% (retinoid) | Acne treatment |
| Adapalene Gel | Adapalene USP 0.1% (retinoid) | Acne treatment |
| Adapalene (store/generic) | Adapalene USP 0.1% (retinoid) | Acne treatment |
| ADAPALENE (labeled listing) | Adapalene USP 0.1% (retinoid) | Acne treatment |
| Unlabeled brand filing | Adapalene, USP 0.1% (retinoid) | Acne treatment |
| Unlabeled brand filing (second) | Adapalene, USP 0.1% (retinoid) | Acne treatment |
What the Labels Warn Against
OTC drug labels are required to carry standardized warning language, and the adapalene filings in this dataset follow that framework. The following points summarize — not reproduce verbatim — what multiple product labels state in their warnings sections.
- External use only. Labels uniformly restrict the product to topical, external application.
- Damaged or compromised skin. Labels instruct consumers not to apply the product to skin that is cut, abraded, affected by eczema, or sunburned. This language appears consistently across the majority of filings reviewed.
- Known allergy. Labels direct consumers not to use the product if they are allergic to adapalene or to any other ingredient listed in the formulation.
- Pregnancy and breastfeeding. Multiple label filings include language advising individuals who are pregnant or breastfeeding to consult a doctor before use. This reflects a precautionary standard common across retinoid-class OTC products.
- Sun exposure. Several label filings specifically mention limiting sun exposure, including exposure from tanning beds, during use. While the warning text is truncated in the API data at this point, the direction to limit UV exposure is present in the majority of product records.
The repeated appearance of these warnings across independent manufacturer filings reflects the FDA’s OTC monograph framework, which standardizes how retinoid-class acne treatments are required to communicate risk to consumers.
Frequently Asked Questions Based on Label Data
What concentration of adapalene is available over the counter, according to label filings?
All eight product records in the openFDA OTC label data list adapalene at 0.1%. No OTC filing in this dataset reflects a different concentration. Labels identify the ingredient as a retinoid at this strength.
What does the official labeled use cover?
Every filing reviewed states a single, consistent indication: “for the treatment of acne.” The labeled purpose across all products is listed as “acne treatment.” Label data does not support broader or additional indications for OTC adapalene products at this concentration.
Are there people the labels say should not use these products?
Yes. Label warnings in the dataset identify two key groups who should not use the product without first speaking to a doctor: individuals who are pregnant or breastfeeding. Additionally, labels state the product should not be used by people with a known allergy to adapalene or other listed ingredients, and should not be applied to damaged skin areas such as cuts, abrasions, eczema patches, or sunburned skin.
Do the labels mention sun exposure?
Multiple filings include a warning directing users to limit sun exposure — explicitly mentioning tanning beds in several records — while using the product. Because the API data captures truncated warning text, the full scope of this guidance may be more detailed on the actual product packaging and accompanying consumer leaflets referenced in the label filings.
A Note on This Article
This article is strictly informational in nature. It describes what official U.S. OTC drug label filings state about adapalene-containing products. It does not constitute medical advice, does not recommend any specific product, and does not provide guidance on skincare routines or treatment plans. Individuals with persistent acne, sensitive skin, or questions about whether any OTC product is appropriate for their situation should consult a licensed dermatologist or qualified healthcare provider.
Data Source
All product-specific information in this article — concentrations, labeled purposes, indications, and warning summaries — was drawn exclusively from the openFDA drug label API (api.fda.gov), with data retrieved on July 16, 2026. openFDA label data reflects manufacturer filings submitted to the U.S. Food and Drug Administration and represents official OTC labeling as filed; it does not necessarily reflect every product currently on retail shelves. Readers seeking the most current label information for a specific product should consult the product packaging directly or the DailyMed database maintained by the National Library of Medicine.